A new publication involving elamipretide was released on September 2, 2026. The paper, titled "The Oxidative-Mitochondrial-Inflammatory Axis in Retinitis Pigmentosa: Extracellular mtDNA as Biomarker and Therapeutic Read-Out," appeared in the journal Antioxidants (Basel, Switzerland).
The publication is indexed under PubMed ID 42792149. No specific findings, results, or conclusions from the paper are included in this report. This brief reflects only the existence and bibliographic details of the publication as provided.
Elamipretide remains an approved compound. Readers interested in the broader context of this compound, including its regulatory status and other published research, can consult the compound overview for additional background.